These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3216 related articles for article (PubMed ID: 25113753)

  • 1. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T
    Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
    Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
    J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
    Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
    Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
    Makita S; Maruyama D; Maeshima AM; Taniguchi H; Yuda S; Toyoda K; Yamauchi N; Fukuhara S; Munakata W; Kobayashi Y; Kurihara H; Izutsu K; Tobinai K
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):108-114. PubMed ID: 31802636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Role of Functional Imaging in the Management of Lymphoma.
    Cheson BD; Meignan M
    Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.
    Cheng G; Chen W; Chamroonrat W; Torigian DA; Zhuang H; Alavi A
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1469-76. PubMed ID: 21505896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 161.